Sohm Inc Stock Price, News & Analysis

SOHM Inc. (OTC PINK:SHMN) has appointed Dr. Lucia Piccotti, PhD, EMBA, to its advisory board to guide the development of cosmeceuticals and personal health products. Dr. Piccotti brings over a decade of experience in biomedical science and business leadership, having served as Senior Director of Strategic Innovation at Kiromic Biopharma and founder of Iguvia LLC, a cosmeceuticals consulting firm. Her background includes significant work at Kimberly-Clark Corporation and expertise in phytoextract-based topical applications. Dr. Piccotti holds a PhD in Biochemistry, focusing on liposomal delivery systems, an MS in Chemistry, and an Executive MBA. Her appointment aims to enhance SOHM's capabilities in developing innovative consumer health solutions.

SOHM, Inc. (OTC:SHMN) has successfully developed a genetically modified ovarian cancer cell line (SKOV3) that overexpresses the GYS1 gene using their proprietary ABBIE™ platform. This breakthrough provides a valuable tool for screening GYS1 inhibitors, as GYS1 is a crucial enzyme in cellular energy metabolism linked to cancer cell survival. The engineered cell line, SKOV3-GYS1+, offers a ready-to-use system for evaluating GYS1-targeted compounds, particularly relevant for aggressive cancers like ovarian, breast, and pancreatic malignancies.

The ABBIE™ platform enables high-specificity gene editing without viral vectors, and SOHM plans to expand its engineered cell line portfolio for metabolic and immuno-oncology targets throughout 2025.

SOHM Inc. (OTC:SHMN) has appointed Dr. Leonardo Mirandola as Advisory Board Member to advance its CAR-T cell projects toward clinical trials. Dr. Mirandola, a biopharma scientist with over a decade of experience in oncology and cell therapy, previously served as CSO and Interim COO at Kiromic Biopharma, where he developed therapies including an FDA Fast-Track-designated allogeneic gamma-delta T-cell therapy for Stage 4 non-small cell lung cancer.

SOHM is leveraging its proprietary gene editing platform, ABBIE, to enhance CAR-T cell therapy commercialization. ABBIE offers advantages over traditional viral-based or CRISPR systems, including cost-efficiency, reduced manufacturing complexity, and fewer regulatory hurdles. The company aims to improve production timelines, genetic payload fidelity, and therapeutic window accessibility.

SOHM Inc. (OTC:SHMN) has secured a European patent for its innovative ABBIE genome editing technology. The patent (No. 3,277,805) specifically covers CAS 9 retroviral integrase and CAS 9 recombinase systems for targeted DNA sequence incorporation into cell or organism genomes. This achievement follows a recent patent grant in South Korea, with the European patent set to be published in the Patent Office Bulletin on May 7, 2025.

According to COO David Aguilar, this technology has significant potential applications in targeted gene therapies, cell therapy development, genetic disorder treatments, and agricultural improvements. The patent grant strengthens SOHM's position in the biotechnology sector and demonstrates its commitment to innovative R&D.

SOHM Inc (OTC PINK:SHMN) has announced a significant licensing agreement with an undisclosed drug development partner for its ABBIE genome editing technology focused on CAR-T cell cancer therapies. The company is set to receive $6 million in funding for advancing joint research initiatives.

The collaboration centers on SOHM's proprietary ABBIE (A Binding-based Integrase Enzyme) integration system, which aims to enhance the safe and efficient production of autologous CAR-T cells. The partnership combines SOHM's integration system with microfluidic gene editing capabilities to develop new micro-dosed CAR-T cell therapies for cancer treatment.

According to COO David Aguilar, PhD, this collaboration will position SOHM and its partners as leaders in microfluidic-based gene editing technology, potentially revolutionizing treatments for cancer and other diseases.

SOHM Inc. (OTC PINK:SHMN) has received a Notice of Allowance/Approval from the South Korea Patent Office for its innovative ABBIE gene editing technology. The patent covers the utilization of CAS 9 RETROVIRAL INTEGRASE and CAS 9 RECOMBINASE SYSTEMS for targeted DNA incorporation into cells or organisms.

This milestone expands SOHM's intellectual property portfolio in a key market, supporting licensing opportunities for novel cell therapies, agriculture, and biofuel applications. The company aims to strengthen its position in the global gene editing and cell therapy market, currently valued at $7.96 billion and $4.74 billion respectively in 2023.

The technology is expected to advance the development of new cell therapies for cancer and congenital diseases, while also supporting biofuel development and crop engineering.

SOHM Inc. (OTC PINK:SHMN) has announced significant developments in its biotechnology operations. The company is expanding its ABBIE genome editing and cell engineering program at their Carlsbad facility and UACI labs to support growing Next-Generation Sequencing (NGS) validation requirements.

The strategic expansion aims to meet increasing demands for engineered mouse models and cell lines important for drug development, gene therapy, and immunotherapy. The company is also enhancing its AI-enabled ABBIE platform for next-generation gene editing applications.

Additionally, SOHM will present a poster titled 'ABBIE Gene Editing: A Breakthrough in Precise, Replicable, and Traceable Genomic Integration' at the American Society of Gene and Cell Therapy Conference, scheduled for May 13-17 in New Orleans, LA.

SOHM Inc. (OTC PINK:SHMN) has announced the formation of a dedicated AI team to enhance its ABBIE (A Binding-based Integrase Enzyme) system and develop novel guide RNAs and RNA guided Integrase fusion proteins. The initiative aims to revolutionize genome editing and cell engineering technologies.

The AI team will utilize machine learning algorithms to optimize guide RNAs and Integrase-dCas fusion proteins design, improving the specificity, efficiency, and versatility of genome editing applications. The company plans to develop next-generation genome editing systems and create engineered cells producing custom exosomes with pharmaceutical properties.

According to COO Dr. David Aguilar, these custom exosomes will serve as targeted delivery vehicles for therapeutic agents, with applications in cancer therapy, regenerative medicine, and immunotherapy. The company aims to design exosomes that can efficiently transport drugs, genes, or RNA molecules to specific tissues.

SOHM Inc (OTC PINK:SHMN) has announced significant developments in their ABBIE Technology, revealing a strategic pivot in their business model. The company is transitioning from selling ABBIE kits for independent use to establishing a licensing model, leveraging their global Intellectual Property portfolio.

The company's breakthrough findings indicate that ABBIE technology features unique traceability capabilities absent in competing technologies, potentially streamlining FDA approval processes and enhancing therapy safety. SOHM is currently in technical diligence discussions with both small innovators and major pharmaceutical companies, focusing on applications in CAR-T therapy, cancer drug development, and gene therapy.

The company plans to publish these findings in Q2 2025 and will organize platform seminars to showcase the technology's potential in revolutionizing cancer treatment.